哮喘
心理干预
疾病
医学
奥马佐单抗
过敏
不利影响
流行病学
免疫球蛋白E
重症监护医学
免疫学
内科学
精神科
抗体
作者
Nikolaos G. Papadopoulos,Michael Miligkos,Paraskevi Xepapadaki
出处
期刊:Handbook of experimental pharmacology
日期:2021-01-01
卷期号:: 69-93
被引量:29
摘要
Asthma is a result of heterogenous, complex gene–environment interactions with variable clinical phenotypes, inflammation, and remodeling. It affects more than 330 million of people worldwide throughout their educational and working lives, while exacerbations put a heavy cost/burden on productivity. Childhood asthma is characterized by a predominance of allergic sensitization and multimorbidity, while in adults polysensitization has been positively associated with asthma occurrence. Despite significant improvements in recent decades, asthma management remains challenging. Recently, a group of specialists suggested that the term “asthma” should be preferably used as a descriptive term for symptoms. Moreover, type 2 inflammation has emerged as a pivotal disease mechanism including overlapping endotypes of specific IgE production, while type 2-low asthma includes several disease endotypes. Optimal asthma control requires both appropriate pharmacological interventions, tailored to each patient, as well as trigger avoidance measures. Regular monitoring for maintenance of symptom control, preservation of lung function, and detection of treatment-related adverse effects are warranted. Allergen-specific immunotherapy and the advent of new targeted therapies for patients with difficult to control asthma offer diverse treatment options. The current review summarizes up-to-date knowledge on epidemiology, definitions, diagnosis, and current therapeutic strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI